ClinicalTrials.gg
CompletedNCT00586612Updated Aug 27, 2018Results posted

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

A Phase 3 interventional study of Menitorix™ and Infanrix™ penta in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 8 sites in Spain. Open to participants aged 8 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Non-randomized
Ages
8 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
50th of 80
313 · median 445
Started
2007
with 3 others
Phase 3
48 of 82
none open now
Registered
37th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 50th largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2007, is one of 48 in phase 3, and was the 37th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 8 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this Phase IIIb study is to evaluate the immunogenicity, reactogenicity \& safety of GSK Biologicals' Hib-MenC vaccine (Menitorix™) when co-administered with GSK Biologicals' DTPa-HBV-IPV vaccine (Infanrix™ penta) \& Wyeth's 7-valent pneumococcal conjugate vaccine (Prevenar™) in preterm infants as a 3-dose primary vaccination course during the first 6 months of life (at 2, 4, 6 months of age) and of a booster dose of Menitorix™ when co-administered with GSK Biologicals' DTPa-IPV vaccine (Infanrix IPV) and Wyeth's Prevenar in the second year of life (16-18 months of age). The control is a group of full-term infants receiving the same vaccines. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

This multicenter study is open \& consists of a primary \& a booster phase. The study has 2 treatment groups (Preterm \& Full-term) that will receive the same vaccinations; the Full-term group will be the active control. Four blood samples will be collected from all subjects for immunogenicity analyses; 2 in the primary phase at prior to the first vaccination and one month after the third vaccination and 2 in the booster phase at prior to booster dose and one month after booster dose.

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Keywords

  • Conjugate vaccine
  • Persistence
  • Hib vaccine
  • Combination vaccine
  • Meningococcal vaccine
  • Safety
  • Preterm/full-term infants
  • Immunogenicity
04

Who can participate

Ages eligible
8 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must satisfy the following criteria at study entry:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 8 and 12 weeks of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.

All preterm subjects must satisfy the following criteria at study entry:

  • Born after a gestation period of less than or equal to 36 weeks (≤258 days).
  • Medically stable, i.e. do not require significant medical support or ongoing management for debilitating disease and have demonstrated a clinical course of sustained recovery.

All full-term subjects must satisfy the following criteria at study entry:

  • Born after a gestation period between and including 37 and 42 weeks (≥259 days and ≤294 days).
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs since birth.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose of vaccine until the last study visit, except measles-mumps-rubella (MMR) and varicella vaccines which may be given according to local immunisation practices and except rotavirus oral vaccine which is allowed at anytime during the study after hospital discharge as per prescribing information.
  • Previous vaccination against diphtheria, tetanus, pertussis, polio, , Haemophilus influenzae type b, meningococcal serogroup C and or Streptococcus pneumoniae disease, with the exception of hepatitis B vaccine or BCG vaccine given in the first month of life according to the national recommendations (although BCG and hepatitis B vaccines should have been given outside a 30-day window from the first administration of study vaccines).
  • History of diphtheria, tetanus, pertussis, polio, hepatitis B, H. influenzae type b, meningococcal disease and or S. pneumoniae disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including (HIV) infection, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins (with the exception of monoclonal antibodies against respiratory syncytial virus [RSV]) and/or any blood products within one month (30 days) preceding the first dose of study vaccines.
  • Planned administration of immunoglobulins and/or any blood products during the active phase of the study.

Specific criteria for the booster part of the study (to be checked at Visit 5, study month 14):

  • History of diphtheria, tetanus, pertussis, polio, hepatitis B, H. influenzae type b, meningococcal disease and or S. pneumoniae disease.
  • Previous vaccination, except the study vaccines and hepatitis birth dose, against diphtheria, tetanus, pertussis, polio, hepatitis B, H. influenzae type b, meningococcal disease and or S. pneumoniae disease.
  • Previous booster vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, H. influenzae type b, meningococcal disease and/or S. pneumoniae disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    Preterm group

    Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.

    Biological: Menitorix™ · Biological: Infanrix™ penta · Biological: Prevenar™ · Biological: Infanrix™ IPV

  • Active comparator
    Full-term group

    Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.

    Biological: Menitorix™ · Biological: Infanrix™ penta · Biological: Prevenar™ · Biological: Infanrix™ IPV

Interventions

  • BiologicalMenitorix™

    Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

  • Intramuscular injection, 3 doses in the primary study

  • BiologicalPrevenar™

    Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.

  • BiologicalInfanrix™ IPV

    Intramuscular injection, 1 dose in the Booster study.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)

    Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of protection.

    Time frame: One month after the third vaccination

  2. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8

    rSBA-MenC titer greater than or equal to 1:8 is indicative of protection.

    Time frame: One month after the third vaccination

Secondary outcomes

  1. Number of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to the Cut-off Values

    Anti-PRP antibody cut-off values assessed include 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.

    Time frame: Before vaccination (at Day 0)

  2. Number of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter

    Anti-PRP antibody cut-off value assessed include 1 microgram per milliliter (µg/mL).

    Time frame: One month after the third vaccination

  3. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

    rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.

    Time frame: Before vaccination (at Day 0)

  4. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

    rSBA-MenC titer cut-off values assessed include 1:32 and 1:128.

    Time frame: One month after the third vaccination

  5. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

    Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.

    Time frame: Before vaccination (at Day 0)

  6. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

    Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.

    Time frame: One month after the third dose

  7. Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

    Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.

    Time frame: Before vaccination (at Day 0)

  8. Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

    Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.

    Time frame: One month after the third dose

  9. Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

    Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).

    Time frame: Before vaccination (at Day 0)

  10. Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

    Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).

    Time frame: One month after the third dose

  11. Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration

    Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).

    Time frame: Before vaccination (at Day 0)

  12. Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration

    Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).

    Time frame: One month after the third dose

  13. Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

    rSBA-MenC titers are given as geometric mean titers (GMTs).

    Time frame: Before vaccination (at Day 0)

  14. Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

    rSBA-MenC titers are given as geometric mean titers (GMTs).

    Time frame: One month after the third dose

  15. Number of Subjects Reporting Solicited Local Symptoms

    Solicited local symptoms assessed include pain, redness and swelling and are presented across doses.

    Time frame: During the 4-day follow-up period after any primary vaccination dose

  16. Number of Subjects Reporting Solicited General Symptoms

    Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite and are presented across doses.

    Time frame: During the 4-day follow-up period after any primary vaccination dose

  17. Number of Subjects Reporting Unsolicited Adverse Events (AEs)

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: Within 31 days after each primary vaccination

  18. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: Throughout the entire primary vaccination phase

  19. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Migrogram Per Milliliter (µg/mL)

    Anti-PRP antibody cut-off value assessed was 0.15 migrogram per milliliter (µg/mL).

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  20. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1.0 Migrogram Per Milliliter (µg/mL)

    Anti-PRP antibody cut-off value assessed was 1.0 migrogram per milliliter (µg/mL).

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  21. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

    rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  22. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to the Cut-off Values

    Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2.0 µg/mL.

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  23. Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to the Cut-off Values

    Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL. Note: the protocol planned an analysis on HBs after the booster dose, but this analysis was not performed as the vaccines administered as booster doses did not contain HBs component.

    Time frame: Prior to (Month 14) the booster vaccination

  24. Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

    Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) in micrograms per milliliter (µg/mL).

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  25. Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration

    Anti-HBs concentrations are given as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). Note: Planned analysis in the protocol of HBs after the booster dose was not performed as booster vaccines did not contain HBs component.

    Time frame: Prior to (Month 14) the booster vaccination

  26. Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

    rSBA-MenC titers are given as geometric mean titers (GMTs).

    Time frame: Prior to (Month 14) and one month after the booster vaccination (Month 15)

  27. Number of Subjects Reporting Solicited Symptoms (Local and General)

    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite.

    Time frame: During the 4-day follow-up period following booster vaccination

  28. Number of Subjects Reporting Unsolicited Adverse Events (AEs)

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: Within 31 days after the booster vaccination (month 15)

  29. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Period 1 is defined as 31 days after last primary vaccination until administration of booster dose (Month 14). Period 2 is defined as the administration of the booster dose until the end of the study (Month 15).

    Time frame: 31 days after last primary vaccination until administration of booster dose (Month 14) and from the administration of the booster dose until the end of the study (Month 15)

07

Results

Posted Jan 22, 2010

Participant flow

Primary Phase
Participant flow — Primary Phase
MilestonePreterm GroupFull-term Group
Started163150
Completed162147
Not completed13
Withdrew: Protocol violation10
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject02
Booster Phase
Participant flow — Booster Phase
MilestonePreterm GroupFull-term Group
Started154144
Completed151143
Not completed31
Withdrew: Lost to follow-up31

Outcome measures

PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)

Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of protection.

Time frame:
One month after the third vaccination
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
subjectsPreterm GroupFull-term Group
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)139141
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8

rSBA-MenC titer greater than or equal to 1:8 is indicative of protection.

Time frame:
One month after the third vaccination
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8
subjectsPreterm GroupFull-term Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:8142140
SecondaryNumber of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to the Cut-off Values

Anti-PRP antibody cut-off values assessed include 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.

Time frame:
Before vaccination (at Day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 0.15 µg/mL3843
≥ 1.0 µg/mL59
SecondaryNumber of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter

Anti-PRP antibody cut-off value assessed include 1 microgram per milliliter (µg/mL).

Time frame:
One month after the third vaccination
Reported as:
Number · subjects
Number of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter
subjectsPreterm GroupFull-term Group
Number of Subject With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1 Microgram Per Milliliter133134
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.

Time frame:
Before vaccination (at Day 0)
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 1:81623
≥ 1:32511
≥ 1:12803
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

rSBA-MenC titer cut-off values assessed include 1:32 and 1:128.

Time frame:
One month after the third vaccination
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 1:32142139
≥ 1:128135136
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.

Time frame:
Before vaccination (at Day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 0.3 µg/mL2336
≥ 2.0 µg/mL38
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2 µg/mL.

Time frame:
One month after the third dose
Reported as:
Number · subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 0.3 µg/mL140141
≥ 2.0 µg/mL127136
SecondaryNumber of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.

Time frame:
Before vaccination (at Day 0)
Reported as:
Number · subjects
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 10 mIU/mL8978
≥ 100 mIU/mL38
SecondaryNumber of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values

Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL.

Time frame:
One month after the third dose
Reported as:
Number · subjects
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to (≥) the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 10 mIU/mL128129
≥ 100 mIU/mL109117
SecondaryAnti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).

Time frame:
Before vaccination (at Day 0)
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
micrograms per milliliter (µg/mL)Preterm GroupFull-term Group
Anti-PRP (n=140, 138)0.116 (0.101 to 0.133)0.140 (0.117 to 0.167)
Anti-PSC (n=142, 137)0.19 (0.17 to 0.22)0.25 (0.21 to 0.30)
SecondaryAnti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) expressed micrograms per milliliter (µg/mL).

Time frame:
One month after the third dose
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
micrograms per milliliter (µg/mL)Preterm GroupFull-term Group
Anti-PRP (n= 140, 142)10.437 (8.398 to 12.970)10.473 (8.547 to 12.833)
Anti-PSC (n= 140, 141)6.34 (5.57 to 7.22)7.46 (6.67 to 8.34)
SecondaryAnti-hepatitis B Surface Antigen (Anti-HBs) Concentration

Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).

Time frame:
Before vaccination (at Day 0)
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
mIU/mLPreterm GroupFull-term Group
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration24.79 (19.82 to 31.00)16.67 (13.52 to 20.56)
SecondaryAnti-hepatitis B Surface Antigen (Anti-HBs) Concentration

Anti-HBs concentrations are given as geometric mean concentrations (GMCs) expressed in milli-international units per milliliter (mIU/mL).

Time frame:
One month after the third dose
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
mIU/mLPreterm GroupFull-term Group
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration372.30 (299.98 to 462.04)586.58 (473.80 to 726.21)
SecondaryMeningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

rSBA-MenC titers are given as geometric mean titers (GMTs).

Time frame:
Before vaccination (at Day 0)
Reported as:
Geometric mean · Titer
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
TiterPreterm GroupFull-term Group
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer4.9 (4.5 to 5.5)5.9 (4.9 to 6.9)
SecondaryMeningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

rSBA-MenC titers are given as geometric mean titers (GMTs).

Time frame:
One month after the third dose
Reported as:
Geometric mean · Titer
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
TiterPreterm GroupFull-term Group
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer1055.9 (859.1 to 1297.7)1346.2 (1130.4 to 1603.1)
SecondaryNumber of Subjects Reporting Solicited Local Symptoms

Solicited local symptoms assessed include pain, redness and swelling and are presented across doses.

Time frame:
During the 4-day follow-up period after any primary vaccination dose
Reported as:
Number · subjects
Number of Subjects Reporting Solicited Local Symptoms
subjectsPreterm GroupFull-term Group
Pain106100
Redness94123
Swelling91113
SecondaryNumber of Subjects Reporting Solicited General Symptoms

Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite and are presented across doses.

Time frame:
During the 4-day follow-up period after any primary vaccination dose
Reported as:
Number · subjects
Number of Subjects Reporting Solicited General Symptoms
subjectsPreterm GroupFull-term Group
Drowsiness111102
Fever8985
Irritability/fussiness128105
Loss of appetite99100
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events (AEs)

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
Within 31 days after each primary vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
subjectsPreterm GroupFull-term Group
Number of Subjects Reporting Unsolicited Adverse Events (AEs)5672
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
Throughout the entire primary vaccination phase
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
subjectsPreterm GroupFull-term Group
Number of Subjects Reporting Serious Adverse Events (SAEs)118
SecondaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Migrogram Per Milliliter (µg/mL)

Anti-PRP antibody cut-off value assessed was 0.15 migrogram per milliliter (µg/mL).

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Migrogram Per Milliliter (µg/mL)
subjectsPreterm GroupFull-term Group
Pre-booster (n= 133; 130)116117
Post-booster (n= 132; 134)132134
SecondaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1.0 Migrogram Per Milliliter (µg/mL)

Anti-PRP antibody cut-off value assessed was 1.0 migrogram per milliliter (µg/mL).

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Number · subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 1.0 Migrogram Per Milliliter (µg/mL)
subjectsPreterm GroupFull-term Group
Pre-booster (n= 133; 130)5353
Post-booster (n= 132; 134)132134
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values

rSBA-MenC titer cut-off values assessed include 1:8, 1:32 and 1:128.

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Number · subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 1:8 pre-booster (n= 134; 134)102117
≥ 1:8 post-booster (n= 133; 137)132136
≥ 1:32 pre-booster (n= 134; 134)95115
≥ 1:32 post-booster (n= 133; 137)132136
≥ 1:128 pre-booster (n= 134; 134)6985
≥ 1:128 post-booster (n= 133; 137)131136
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to the Cut-off Values

Anti-PSC antibody cut-off values assessed include 0.3 micrograms per milliliter (µg/mL) and 2.0 µg/mL.

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Number · subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 0.3 µg/mL pre-booster (n= 130; 127)7492
≥ 0.3 µg/mL post-booster (n= 117; 129)116129
≥ 2.0 µg/mL pre-booster (n= 130; 127)1111
≥ 2.0 µg/mL post-booster (n= 117; 129)105124
SecondaryNumber of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to the Cut-off Values

Anti-HBs antibody cut-off values assessed include 10 milli-international units per milliliter (mIU/mL) and 100 mIU/mL. Note: the protocol planned an analysis on HBs after the booster dose, but this analysis was not performed as the vaccines administered as booster doses did not contain HBs component.

Time frame:
Prior to (Month 14) the booster vaccination
Reported as:
Number · subjects
Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration Greater Than or Equal to the Cut-off Values
subjectsPreterm GroupFull-term Group
≥ 10 mIU/mL pre-booster121113
≥ 100 mIU/mL pre-booster6171
SecondaryAnti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration

Anti-PRP and anti-PSC concentrations are given as geometric mean concentrations (GMCs) in micrograms per milliliter (µg/mL).

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Anti-polyribosylribitol Phosphate (Anti-PRP) and Anti-polysaccharide C (Anti-PSC) Concentration
micrograms per milliliter (µg/mL)Preterm GroupFull-term Group
anti-PRP pre-booster (n= 133; 130)0.706 (0.565 to 0.881)0.777 (0.622 to 0.972)
anti-PRP post-booster (n= 132; 134)50.343 (41.627 to 60.884)54.625 (45.325 to 65.834)
anti-PSC pre-booster (n= 130; 127)0.42 (0.35 to 0.51)0.56 (0.47 to 0.67)
anti-PSC post-booster (n= 117; 129)10.06 (8.14 to 12.45)11.31 (9.60 to 13.31)
SecondaryAnti-hepatitis B Surface Antigen (Anti-HBs) Concentration

Anti-HBs concentrations are given as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). Note: Planned analysis in the protocol of HBs after the booster dose was not performed as booster vaccines did not contain HBs component.

Time frame:
Prior to (Month 14) the booster vaccination
Reported as:
Geometric mean · mIU/mL
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration
mIU/mLPreterm GroupFull-term Group
Anti-hepatitis B Surface Antigen (Anti-HBs) Concentration95.9 (75.6 to 121.5)145.6 (112.1 to 189.1)
SecondaryMeningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer

rSBA-MenC titers are given as geometric mean titers (GMTs).

Time frame:
Prior to (Month 14) and one month after the booster vaccination (Month 15)
Reported as:
Geometric mean · titer
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titer
titerPreterm GroupFull-term Group
Pre-booster (n= 134; 134)79.3 (56.3 to 111.8)147.8 (110.9 to 197.1)
Post-booster (n= 133; 137)4883.1 (3783.1 to 6302.9)5288.8 (4244.9 to 6589.4)
SecondaryNumber of Subjects Reporting Solicited Symptoms (Local and General)

Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability/fussiness and loss of appetite.

Time frame:
During the 4-day follow-up period following booster vaccination
Reported as:
Number · subjects
Number of Subjects Reporting Solicited Symptoms (Local and General)
subjectsPreterm GroupFull-term Group
Pain8298
Redness77109
Swelling6794
Drowsiness3346
Fever4353
Irritability7069
Loss of appetite3450
SecondaryNumber of Subjects Reporting Unsolicited Adverse Events (AEs)

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
Within 31 days after the booster vaccination (month 15)
Reported as:
Number · subjects
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
subjectsPreterm GroupFull-term Group
Number of Subjects Reporting Unsolicited Adverse Events (AEs)3442
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Period 1 is defined as 31 days after last primary vaccination until administration of booster dose (Month 14). Period 2 is defined as the administration of the booster dose until the end of the study (Month 15).

Time frame:
31 days after last primary vaccination until administration of booster dose (Month 14) and from the administration of the booster dose until the end of the study (Month 15)
Reported as:
Number · subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
subjectsPreterm GroupFull-term Group
Period 1102
Period 210

Adverse events

Collected over For SAEs: the whole study period (Day 0 - Month 15); For frequent adverse events: solicited adverse events a 4-day period after vaccination, unsolicited adverse events a 31-day period after vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Preterm Group—22/163 (13.5%)153/163 (93.9%)
Full-term Group—10/150 (6.7%)144/150 (96%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPreterm GroupFull-term Group
BronchiolitisInfections and infestations6/1632/150
PneumoniaInfections and infestations4/1631/150
BronchospasmRespiratory, thoracic and mediastinal disorders4/1630/150
Upper respiratory tract infectionInfections and infestations3/1630/150
Gastroenteritis rotavirusInfections and infestations0/1632/150
Respiratory syncytial virus bronchiolitisInfections and infestations1/1631/150
GastroenteritisInfections and infestations1/1631/150
Lower respiratory tract infectionInfections and infestations1/1631/150
Meningococcal sepsisInfections and infestations0/1631/150
OsteomyelitisInfections and infestations0/1631/150
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPreterm GroupFull-term Group
RednessGeneral disorders94/163123/150
Irritability/fussinessGeneral disorders128/163105/150
RednessGeneral disorders77/154109/144
SwellingGeneral disorders91/163113/150
DrowsinessGeneral disorders111/163102/150
PainGeneral disorders82/15498/144
PainGeneral disorders106/163100/150
Loss of appetiteGeneral disorders99/163100/150
SwellingGeneral disorders67/15494/144
FeverGeneral disorders89/16385/150

Baseline characteristics

Age, Continuous
Age, Continuous(weeks)Preterm GroupFull-term GroupTotal
Mean8.9 ± 1.158.8 ± 0.798.9 ± 0.99
Sex: Female, Male
Sex: Female, Male(Participants)Preterm GroupFull-term GroupTotal
Female7765142
Male8685171
08

Study locations

8 sites
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Bilbao, 48013, Spain
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Getafe, 28905, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28047, Spain
  • GSK Investigational Site
    Malaga, 29010, Spain
  • GSK Investigational Site
    Móstoles/Madrid, 28935, Spain
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 4, 2008
Start
Dec 1, 2007
Primary completionActual
Dec 30, 2008
CompletionActual
Dec 30, 2008
Results first posted
Jan 22, 2010
Last update
Aug 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00586612
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 4, 2008
Start date
Dec 1, 2007
Primary completion
Dec 30, 2008
Completion
Dec 30, 2008
Results posted
Jan 22, 2010
Last update
Aug 27, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pediarix · Heptavalent Pneumococcal Conjugate Vaccine

Start the discussion